SPYRE THERAPEUTICS INC.
NASDAQ: SYRE (Spyre Therapeutics, Inc.)
Last update: 10 hours ago15.76
0.26 (1.68%)
| Previous Close | 15.50 |
| Open | 15.53 |
| Volume | 506,667 |
| Avg. Volume (3M) | 616,350 |
| Market Cap | 951,172,736 |
| Price / Sales | 650.22 |
| Price / Book | 2.86 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Spyre Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fairmount Funds Management Llc | 31 Mar 2025 | 4,018,101 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2025 | 2,127,205 |
| 52 Weeks Range | ||
| Median | 45.00 (185.53%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 08 Apr 2025 | 45.00 (185.53%) | Buy | 11.80 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |